HCRTR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL204028	0.58	20/20
SCHEMBL80489	0.56	20/20
SCHEMBL263053	0.54	19/20
Almorexant (SCHEMBL196577)	1.00	18/20
SCHEMBL261791	0.69	18/20
SCHEMBL262353	0.69	18/20
SCHEMBL261968	0.67	18/20
SCHEMBL204876	0.51	18/20
SCHEMBL198063	1.00	16/20
SCHEMBL198064	1.00	16/20
SCHEMBL171698	0.43	16/20
SCHEMBL262757	0.53	15/20
Hydrochloric Acid (SCHEMBL262382)	0.52	15/20
SCHEMBL261755	0.52	15/20
SCHEMBL264270	0.50	15/20
SCHEMBL196581	1.00	14/20
SCHEMBL196582	1.00	14/20
SCHEMBL246714	1.00	14/20
SCHEMBL268642	0.76	14/20
SCHEMBL269282	0.80	13/20

Clinical trials — most relevant to HCRTR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease	PHASE4	NOT_YET_RECRUITING
Lemborexant Shift Work Treatment Study	PHASE4	COMPLETED
The Role of Orexin in Human Panic Disorder	PHASE4	COMPLETED
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial	PHASE4	RECRUITING
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial	PHASE2/PHASE3	COMPLETED
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy	PHASE3	RECRUITING
DORA and LP in Alzheimer's Disease Biomarkers	PHASE2	RECRUITING
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use	PHASE2	COMPLETED
Analyzing Female Trauma Exposed Responses to a Medication	PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy	PHASE2	RECRUITING
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping	PHASE2	NOT_YET_RECRUITING
Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant	PHASE2	UNKNOWN
Targeting Orexin to Treat Nicotine Dependence	PHASE1	UNKNOWN
Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy	PHASE1	COMPLETED
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia	EARLY_PHASE1	WITHDRAWN
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism	nan	NOT_YET_RECRUITING
Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence	nan	RECRUITING
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations	nan	NOT_YET_RECRUITING
Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714	nan	COMPLETED
Digital Addiction, Sleep Quality and Orexin-A Level	nan	COMPLETED
Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence	nan	UNKNOWN
A Multi-Signal Based Monitoring System for CNS Hypersomnias	nan	UNKNOWN
Impact of Sleep and Meal Timing on Food Intake Regulation	nan	COMPLETED
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy	nan	UNKNOWN
Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition	nan	UNKNOWN
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees	nan	COMPLETED
Pediatric Cohort Study	nan	UNKNOWN
Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HCRTR1 binder may also engage these)

Protein	Name	Similarity
O97661	—	1.000	O97661 →
P56718	—	1.000	P56718 →
Q0GBZ5	—	1.000	Q0GBZ5 →
P58307	—	1.000	P58307 →
O62809	—	0.994	O62809 →
Q9EP86	—	0.991	Q9EP86 →
Q9TUP7	—	0.987	Q9TUP7 →
P58308	—	0.986	P58308 →
NPFFR1	Neuropeptide FF receptor 1	0.984	landscape →
HCRTR2	Orexin receptor type 2	0.981	landscape →
Q8BGE9	—	0.979	Q8BGE9 →
P56719	—	0.978	P56719 →
RXFP3	Relaxin-3 receptor 1	0.977	landscape →
P30935	—	0.976	P30935 →
P30936	—	0.975	P30936 →
Q9EQD2	—	0.972	Q9EQD2 →
Q924H0	—	0.972	Q924H0 →
Q9Y5Y3	—	0.972	Q9Y5Y3 →
P49660	—	0.972	P49660 →
P97295	—	0.971	P97295 →
Q9JKL1	—	0.971	Q9JKL1 →
P11617	—	0.968	P11617 →
Q8K458	—	0.968	Q8K458 →
Q9NYM4	—	0.966	Q9NYM4 →
SSTR3	Somatostatin receptor type 3	0.966	landscape →
Q9TTQ9	—	0.966	Q9TTQ9 →
Q60613	—	0.965	Q60613 →
Q9EQQ4	—	0.965	Q9EQQ4 →
Q9WV08	—	0.965	Q9WV08 →
Q8VIH9	—	0.965	Q8VIH9 →